Skip to main content

Table 4 Main factors motivating the start of a treatment with glatiramer acetate

From: Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients

Reason to start glatiramer acetate

Overall n = 145 (%)

Naïve n = 92 (%)

Switchers n = 53 (%)

Avoid flu–like syndrome / side effect profile

48

33 (36)

15 (28)

Depression / fatigue / cognitive problems

37

29 (31)

8 (15)

Comorbidities

13

4 (4)

9 (17)

Low disease activity

11

7 (8)

4 (8)

Pregnancy planning

10

6 (7)

4 (8)

JCV+ status

8

1 (1)

7 (13)

Patient’s choice

7

7 (8)

0

Others

11

5 (5)

6 (11)